Drug Manufacturers

Integrated Downstream Processing

By LEWA

Over the last decades, the pharmaceutical industry has invested a tremendous amount of resources and capital into the development of continuous processes to improve process efficiency and robustness.

Increasing expression levels in modern cell culture and implementing continuous upstream processes has caused the downstream purification to become the 'bottleneck' in the manufacturing of biopharmaceuticals, especially of monoclonal antibodies.

Download to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.